HUE028163T2 - Polialkilén polimervegyületek és felhasználásuk - Google Patents

Polialkilén polimervegyületek és felhasználásuk Download PDF

Info

Publication number
HUE028163T2
HUE028163T2 HUE03731987A HUE03731987A HUE028163T2 HU E028163 T2 HUE028163 T2 HU E028163T2 HU E03731987 A HUE03731987 A HU E03731987A HU E03731987 A HUE03731987 A HU E03731987A HU E028163 T2 HUE028163 T2 HU E028163T2
Authority
HU
Hungary
Prior art keywords
ifn
group
biologically
alkyl
kda
Prior art date
Application number
HUE03731987A
Other languages
English (en)
Inventor
Kochung Lin
R Blake Pepinsky
Ling Ling Chen
Donna M Hess
Edward Y Lin
Russell C Petter
Darren P Baker
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HUE028163T2 publication Critical patent/HUE028163T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)

Claims (4)

  1. Szabadalmi igè&y$etni®k l , A XXla képfei szerinti szerkezeté feôspgSîatn; XXIla képiéi:
    ahol P jelentése egy poHalklleo-ghkoi polimer; X jelentése O; Z je&dhfee egyenes vágy elágazó lápéig telített vagy seiitetlen, í-10 s&xmMmfeté. «Mr vagy hetemalkil-esopoFt, 3-& S2àtî»î®«æ8mô, MíMí vagy töiíMleo* p&iasés vagy dklmos: ííekífoalítikesípírí, sznbsztitoáit vagy mm sztíbsziiiiíátt aril- vagy inderoarihesogort vagy asm szobszÂtâlt aftmteôpwt, ahol a* :$IS egy M® szánstomszáaso, teiiíett vagy telítetíea a|p~ vagy hsteroalksrfesspod, ahol a szutettaeasefcá esoporihol válsgzMak: halogén,, hidroxik karboml, karboxilát, ÉSr, forrni!, adl, tiokarbonlt, tM$%m tioaeetéh íroíomáí, aikoxik foszford, htszinnáh fesztpái, mim, atnido, amhS»,. Imin, ciano, rmro, azido, szalthkiril, szalßfe szid (boát, szoífamoil, szudboaondo, szobórdi, bek-.roctkyi. araik si aromás funkciós csoport. heiergaromá» ihokeias esoport, ««ásó·» szilit, éter ás aikiltiok E* jelentése egy összeköti! csoport, amely abban a reakcióban képződik, amely egy, az aldehid, aid#!«-' hidrát és acélát közit választott csoport, valántiM egy biöiógiaitag aktiv vegyidet közölt zajlik; B jelentése egy biológiailag, aktív vegyidét., ahol 8 biológiailag aktiv vegyidet egy interlerombéia; és s jelentése; 8: vagy egy 1 és 5 közötti egész szám,·
  2. 2. Az; L Igénypont szerinti kospgátum, aboi P jelentése a 11 képet szedni! szerkezetű poiíeiitén-gíikoí.: ti képlet: E-C0~O'irÖIrV aheí B jeléhtéso: hiddtgiht, egy egyenes vagy elágazó láncé, Epszénatomszlsnd áikihcsopori vagy egy detektálható jelölik és: á Jéleotése ggy:4 és HkÄ) között 1 egész száin, 2. ,4 2i. igénypont szerinti konjngilhon, ahol B jelentése meíil 4 A 2. igénypont szerinti konjogtan, ahol B jeien-ese egy deíéktáiitató jelöld, 5:. A 4, Igénypont szerimi liorjugéiuíft,, almi B a következő esgporlhój választóit; radioaktiv kotógök, ítu-otsszeens feokeiós csoportok, tbsztlAeezeehS: fenkdós csoportok, kemitnmheszeens fekeiós «söpörtök ék kvamumpontok. b, A korábbi igényponiPk bárntslyike szerinti sonjugátmn, ahol X jelentése metál és «jelentése egy.
    2. A korábbi igénypontéi tsáAnelyike szerinti fenjugáíunh ahol ·&« jelentésé meiüéh és B jelentése egy amiaOskerésztíit kapcsolódó ír«srletö«-béta, & A 7, igénypont szerinti ksmpgátum, ahol az amin az mtefietm-béts ánssodehiioáljsá,
  3. 9. A korábbi igénypontok hármeiyike szerinti konjagátnuz, ahol az införiiron-béta az InierleraodÄd a. 1Ö, Az I. igéoypost szerinti Isagt^áintn, aboi a kot^ngáttna a 20 köa ntolefeulaíömegS mPEG-CX2~meíi· prnptöríaidehiddei: módísittól: intmfce8'béta-la, ahnt az interlinöödiéta-la az E^ermináíisának; amitpn keresztül kapcsolódik a 20 kDa maíeknlatösnegé kfldXi -O-2 -nietil-propioraddehidhez. ILöy^yászaíl fcésriîpéîiy, apély tarMraa? l-íö. íf^jrf&stofc Mrmdy#« s;pÄi kööjugáíumot és gyi>gyás/iű?!sg ellogadbalö teiozét \ 2. Az MO jgéîîypiÂîk feàfî:8«:ÿÈé szériád larilpglibi® ôlpp béïég késelésében íxbtéftS alkalmazásra, aki errs fogékony vírussal fénôzôît. IXKampgábsm a 12. ígérsypöoí szemll alkalmazásra, alsót a kezelés sartateazza: egy, a ko vetkezőkből allé ssopsiMI válassfori vlraselteas szer beadását Is: ribavirin, íevwfcü»,. 3TC, FTC, MBbSő, zidbvudine, aeydovir, gancydövlr, v iramúié, VíK-éŐ?. VX-950 és ISIS-I4803. ÍN. Konpgáínm a 12. jgésypöfcí a vímsíériiSsés krónikus bepstitls €:. 1?. Az 1-10, Igétiypontbk Mrptpiyske sériait totj«gài«f» ^aj#^i>ft«Ni#|^égb8R .szeövedf '&aite|:'&ezeM-Séfeiró löríésb sikabnnzasrs. IfotGmpgáíMi a !5. igéayppt szerinti felhasználtok, íátril m snfoimnpn-bmegseg «:terÄ msilílglek.
  4. 17. Az I - ! 0, igéssypörifok btadyto: szériát! kösglsgátoss: terápiában fonásé alkateázisfá,
HUE03731987A 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk HUE028163T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34991702P 2002-01-18 2002-01-18

Publications (1)

Publication Number Publication Date
HUE028163T2 true HUE028163T2 (hu) 2016-11-28

Family

ID=27613339

Family Applications (4)

Application Number Title Priority Date Filing Date
HU0500457A HU230473B1 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és azok alkalmazása
HUE03731987A HUE028163T2 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk
HUE15203017A HUE047557T2 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk
HUS1600035C HUS1600035I1 (hu) 2002-01-18 2016-08-18 Polialkilén polimervegyületek és felhasználásuk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0500457A HU230473B1 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és azok alkalmazása

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE15203017A HUE047557T2 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk
HUS1600035C HUS1600035I1 (hu) 2002-01-18 2016-08-18 Polialkilén polimervegyületek és felhasználásuk

Country Status (35)

Country Link
US (2) US8017733B2 (hu)
EP (3) EP3669887A1 (hu)
JP (5) JP2005526151A (hu)
KR (1) KR100964411B1 (hu)
CN (2) CN1630530A (hu)
AU (1) AU2003210564B2 (hu)
BE (1) BE2016C040I2 (hu)
BG (1) BG66525B1 (hu)
BR (1) BRPI0306993B8 (hu)
CA (4) CA2473526C (hu)
CY (2) CY2016027I2 (hu)
CZ (1) CZ2004877A3 (hu)
DK (2) DK3025726T3 (hu)
EA (2) EA009783B1 (hu)
EE (1) EE05509B1 (hu)
ES (2) ES2566797T3 (hu)
GE (2) GEP20064024B (hu)
HK (3) HK1072721A1 (hu)
HU (4) HU230473B1 (hu)
IL (1) IL163006A (hu)
IS (1) IS2989B (hu)
LU (1) LU93162I2 (hu)
ME (2) ME00239B (hu)
MX (1) MXPA04006855A (hu)
NL (1) NL300826I2 (hu)
NO (3) NO339857B1 (hu)
NZ (1) NZ534708A (hu)
PL (2) PL397261A1 (hu)
PT (1) PT3025726T (hu)
RS (1) RS55578B1 (hu)
SI (2) SI3025726T1 (hu)
SK (1) SK3102004A3 (hu)
UA (1) UA82184C2 (hu)
WO (1) WO2003061577A2 (hu)
ZA (1) ZA200406555B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566797T3 (es) * 2002-01-18 2016-04-15 Biogen Ma Inc. Compuestos de polímero de polialquileno y usos de éstos
US20150246097A9 (en) * 2002-01-18 2015-09-03 Biogen Idec Ma Inc. Polyalkylene Polymer Compounds and Uses Thereof
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
BR0317752A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP2044959A1 (en) 2003-06-26 2009-04-08 pSivida Inc In-situ gelling drug delivery system
JP5628467B2 (ja) 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
US20090312344A1 (en) * 2004-05-31 2009-12-17 Mohammad Salman Arylpiperazine derivatives as adrenergic receptor antagonists
CA2591233C (en) 2004-12-21 2014-10-07 Nektar Therapeutics Al, Corporation Stabilized polymeric thiol reagents
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
SG163565A1 (en) * 2005-07-08 2010-08-30 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
MX2008014520A (es) * 2006-05-22 2008-11-27 Elan Pharm Inc Preparacion de conjugados polimericos de compuestos terapeuticos, agricolas, y de aditivos para alimentos.
WO2008066816A2 (en) * 2006-11-28 2008-06-05 The Board Of Trustees Of The University Of Illinois Derivatization or ligaton of peptides
JP2010533202A (ja) * 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
US20090017004A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CN103536906A (zh) * 2008-06-05 2014-01-29 津莫吉尼蒂克斯公司 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎
US8273343B2 (en) * 2008-07-31 2012-09-25 Pharmaessentia Corp. Protein-polymer conjugates
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
WO2010140350A1 (ja) 2009-06-02 2010-12-09 パナソニック株式会社 ダウンミックス装置、符号化装置、及びこれらの方法
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
EP3183264B1 (en) 2014-08-19 2020-07-29 Biogen MA Inc. Pegylation method
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
ES2831079T3 (es) * 2017-06-28 2021-06-07 Construction Research & Technology Gmbh Dispersante para partículas inorgánicas
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
CN109232898A (zh) * 2018-08-02 2019-01-18 张玲 一种具有抗凝血功能的聚酰亚胺新材料的制备方法
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
CN113716982B (zh) * 2021-08-24 2022-05-06 重庆云瑞肥业有限公司 一种食品垃圾回收用发酵制肥装置

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1996017929A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AU730969B2 (en) * 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
EP0975809A4 (en) 1997-03-05 2002-10-30 Univ Washington EXAMINATION PROCEDURE FOR DETECTING AGENTS FOR SELECTIVE INHIBITION OF HCV REPLICATION
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP4465109B2 (ja) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
ATE268609T1 (de) * 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
PT1421956E (pt) * 1998-04-28 2007-07-13 Serono Lab Processo para a ligação por passos de polietileno glicol ( peg ) a um polipéptido
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
TR200101086T2 (tr) * 1998-10-16 2001-08-21 Biogen, Inc. Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
JP2003503367A (ja) * 1999-06-11 2003-01-28 シアウォーター・コーポレイション キトサンとポリ（エチレングリコール）または関連ポリマーから得られるヒドロゲル
EP1328295A2 (en) 1999-08-27 2003-07-23 Maxygen Aps New interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
EP1259562B1 (en) 1999-12-22 2006-02-15 Nektar Therapeutics Al, Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP2295450B1 (en) * 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
EE05537B1 (et) * 2001-02-01 2012-04-16 Biogen, Inc. Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks
HUP0303251A2 (hu) 2001-02-27 2003-12-29 Maxygen Aps Béta-interferon-szerű molekulák
US7009033B2 (en) * 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
EP2939696B1 (en) * 2001-10-18 2016-03-09 Nektar Therapeutics Polymer conjugates of opioid antagonists
EA008505B1 (ru) * 2001-11-20 2007-06-29 Фармация Корпорейшн Конъюгаты химически модифицированного гормона роста человека
KR100488351B1 (ko) * 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
ES2566797T3 (es) 2002-01-18 2016-04-15 Biogen Ma Inc. Compuestos de polímero de polialquileno y usos de éstos
RS20050202A (en) * 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy

Also Published As

Publication number Publication date
CN1630530A (zh) 2005-06-22
CY2016027I1 (el) 2017-06-28
IL163006A (en) 2011-01-31
EP3025726B1 (en) 2019-11-20
NZ534708A (en) 2007-05-31
MXPA04006855A (es) 2005-04-19
JP2016014022A (ja) 2016-01-28
WO2003061577A2 (en) 2003-07-31
HUP0500457A2 (hu) 2005-08-29
NO20151082A1 (no) 2015-08-26
HK1072721A1 (zh) 2005-09-09
DK1476181T3 (en) 2016-05-23
EP3025726A1 (en) 2016-06-01
SK3102004A3 (sk) 2005-01-03
JP5275125B2 (ja) 2013-08-28
EP1476181A2 (en) 2004-11-17
CA2473526A1 (en) 2003-07-31
BG108839A (bg) 2005-04-30
JP2013136756A (ja) 2013-07-11
EE200400105A (et) 2004-12-15
HUP0500457A3 (en) 2012-09-28
BE2016C040I2 (hu) 2022-05-17
JP2009235409A (ja) 2009-10-15
BR0306993A (pt) 2005-09-06
US20120014916A1 (en) 2012-01-19
BRPI0306993B8 (pt) 2021-05-25
PL397261A1 (pl) 2012-03-26
AU2003210564B2 (en) 2008-10-23
EA200400962A1 (ru) 2005-06-30
HK1143553A1 (en) 2011-01-07
EA009783B1 (ru) 2008-04-28
US8524660B2 (en) 2013-09-03
HUS1600035I1 (hu) 2016-10-28
PL213322B1 (pl) 2013-02-28
BG66525B1 (bg) 2016-04-28
WO2003061577A8 (en) 2008-11-20
RS55578B1 (sr) 2017-06-30
SI1476181T1 (sl) 2016-10-28
SI3025726T1 (sl) 2020-03-31
WO2003061577A3 (en) 2003-10-02
NO2017013I1 (no) 2017-04-10
ZA200406555B (en) 2005-11-30
ME00239B (me) 2011-05-10
CN101700401B (zh) 2013-08-14
HU230473B1 (hu) 2016-07-28
IS7353A (is) 2004-07-15
RS63504A (en) 2007-02-05
CY2016027I2 (el) 2017-06-28
ES2566797T3 (es) 2016-04-15
JP2012255156A (ja) 2012-12-27
PL372728A1 (en) 2005-08-08
US8017733B2 (en) 2011-09-13
HK1224185A1 (zh) 2017-08-18
EP1476181B1 (en) 2016-03-23
MEP35608A (en) 2011-02-10
CY1122841T1 (el) 2021-10-29
JP2005526151A (ja) 2005-09-02
CA2753899C (en) 2014-03-25
EE05509B1 (et) 2012-02-15
PT3025726T (pt) 2020-01-09
CZ2004877A3 (cs) 2004-12-15
NO2017013I2 (no) 2018-08-20
BRPI0306993B1 (pt) 2020-03-10
US20050107277A1 (en) 2005-05-19
CA2473526C (en) 2013-10-22
NL300826I2 (hu) 2017-03-16
EP3669887A1 (en) 2020-06-24
NO20043422L (no) 2004-10-11
CN101700401A (zh) 2010-05-05
KR100964411B1 (ko) 2010-06-15
EA011829B1 (ru) 2009-06-30
NO339857B1 (no) 2017-02-06
CA2952488C (en) 2019-05-07
CA2753899A1 (en) 2003-07-31
GEP20064024B (en) 2007-01-10
ES2774801T3 (es) 2020-07-22
CA2952488A1 (en) 2003-07-31
EA200701386A1 (ru) 2007-10-26
CA2840490C (en) 2017-02-28
EP1476181A4 (en) 2008-11-19
DK3025726T3 (da) 2019-12-09
UA82184C2 (uk) 2008-03-25
IS2989B (is) 2017-11-15
JP6030717B2 (ja) 2016-11-24
GEP20074024B (en) 2007-01-10
HUE047557T2 (hu) 2020-04-28
LU93162I2 (fr) 2016-10-03
CA2840490A1 (en) 2003-07-31
NO344612B1 (no) 2020-02-10
KR20040081463A (ko) 2004-09-21

Similar Documents

Publication Publication Date Title
EP1476181B1 (en) Polyalkylene polymer compounds and uses thereof
AU2003210564A1 (en) Polyalkylene glycol with moiety for conjugating biologically active compound
JP2005526151A5 (hu)
US20170049904A1 (en) Polyalkylene polymer compounds and uses thereof